Source: NeurologyLive
At the 2025 AD/PD International Conference on Alzheimer’s and Parkinson’s Diseases, held April 1-5 in Vienna, Austria, Quanterix presented over 80 posters, presentations, and sessions that featured our Simoa technology. Over the years, Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum, or plasma, with the ability to quantify proteins that are far lower than the level of quantification.
During the meeting, NeurologyLive® sat down with Mark Roskey, PhD, chief scientific officer at Quanterix, to discuss the company’s technology, its function, and role in the diagnosis of AD. In the discussion, Roskey highlighted the critical role of phosphorylated tau (p-tau)217 as the leading biomarker for early detection and disease monitoring, as well as advancements in multiplex biomarker panels that combine markers like glial fibrillary acidic protein (GFAP), neurofilament light (NfL), and amyloid proteins for more comprehensive analysis. In addition, he spoke on the recently introduced Lucent AD Complete, a newly launched diagnostic tool designed to improve clarity in AD testing by reducing ambiguous results.
Related Posts
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
Neurology
AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics
Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of…